3 ms·

Yup, and the infectious theory is the one that's gradually getting more and more mainstream traction (the premise being that beta amyloid has a tactical immune

Yup, and the infectious theory is the one that's gradually getting more and more mainstream traction (the premise being that beta amyloid has a tactical immune function in the brain but trades short-term success against pathogens at the expense of long term longevity in people who can't clear the plaques out effectively with restful sleep). Good Google scholar queries include 'hsv apoe4' as well as 'gingivitis alzheimers', without quotes, and among others. I can dig up my past comments that went into depth on all the different studies here, but a lot of doctors have yet to be swayed on the new theory. Edit: found a good reference page with all the different trials going on around different theories for Alzheimer's, including the infectious theory. http://www.cumc.columbia.edu/adrc/patients-and-families/clinical-trials http://www.cumc.columbia.edu/adrc/patients-and-families/clin... has all the current trials https://clinicaltrials.gov/ct2/show/NCT03282916 https://clinicaltrials.gov/ct2/show/NCT03282916 is the valacyclovir trial trying to replicate the 2018 results out of Taiwan. A different angle is the recently discussed correlation between lithium intake and Alzheimer's, and that's also being explored: https://clinicaltrials.gov/ct2/show/NCT02129348 https://clinicaltrials.gov/ct2/show/NCT02129348

atombender 7y ago
That clinical trials list doesn't mention the GAIN phase 2/3 trial [1] [2] currently underway to test COR388 from Cortexyme [3]. It's a small molecule that targets gingipains, cysteine proteases of the P. gingivalis, a periodontal pathogen responsible for gingivitis that has been found in Alzheimer's patients. Here [4] is a paper on the gingivalis hypothesis funded by Cortexyme. [1] https://clinicaltrials.gov/ct2/show/NCT03823404?term=NCT03823404&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT03823404?term=NCT0382... [2] https://gaintrial.com/en/about https://gaintrial.com/en/about [3] https://www.cortexyme.com/?page_id=6022 https://www.cortexyme.com/?page_id=6022 [4] https://advances.sciencemag.org/content/5/1/eaau3333 https://advances.sciencemag.org/content/5/1/eaau3333
nextos 7y ago
It's not necessarily pathogens only but it can also be commensal dysbiosis. See the discussion linked by the parent comment or my other comment here. We should start thinking about all diseases that involve the HLA gene and dysfunctional immune responses as autoimmunity. Not just the obvious ones. Hence the question is simply why is the immune system misclassifying our own tissues? It's a CS / information theory problem.

atombender 7y ago

That clinical trials list doesn't mention the GAIN phase 2/3 trial [1] [2] currently underway to test COR388 from Cortexyme [3]. It's a small molecule that targets gingipains, cysteine proteases of the P. gingivalis, a periodontal pathogen responsible for gingivitis that has been found in Alzheimer's patients. Here [4] is a paper on the gingivalis hypothesis funded by Cortexyme. [1] https://clinicaltrials.gov/ct2/show/NCT03823404?term=NCT03823404&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT03823404?term=NCT0382... [2] https://gaintrial.com/en/about https://gaintrial.com/en/about [3] https://www.cortexyme.com/?page_id=6022 https://www.cortexyme.com/?page_id=6022 [4] https://advances.sciencemag.org/content/5/1/eaau3333 https://advances.sciencemag.org/content/5/1/eaau3333

nextos 7y ago

It's not necessarily pathogens only but it can also be commensal dysbiosis. See the discussion linked by the parent comment or my other comment here. We should start thinking about all diseases that involve the HLA gene and dysfunctional immune responses as autoimmunity. Not just the obvious ones. Hence the question is simply why is the immune system misclassifying our own tissues? It's a CS / information theory problem.